Dominik Paul Modest

Summary

Affiliation: University of Munich
Country: Germany

Publications

  1. doi request reprint [Chemotherapy of metastatic colorectal cancer]
    D P Modest
    Medizinische Klinik und Poliklinik III and Comprehensive Cancer Center, Klinikum der Universitat Munchen, Marchioninistr 15, 81377, Munchen, Deutschland
    Internist (Berl) 55:37-42. 2014
  2. pmc Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group
    Anke Reinacher-Schick
    Department of Internal Medicine, Knappschaftskrankenhaus, Ruhr University Bochum, Bochum, Germany
    BMC Cancer 12:349. 2012
  3. doi request reprint KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer
    D P Modest
    Department of Medicine III, University Hospital Grosshadern, University of Munich, Munich, Germany
    J Cancer Res Clin Oncol 139:953-61. 2013
  4. ncbi request reprint Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials
    Dominik P Modest
    Department of Medicine III, University Hospital Grosshadern, University of Munich, Munich, Germany
    Oncology 83:241-7. 2012
  5. doi request reprint Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis
    Dominik Paul Modest
    Department of Medicine III, Klinikum Grosshadern, University of Munich, Munich, Germany
    Anticancer Drugs 23:666-73. 2012
  6. doi request reprint The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: an analysis of the AIO KRK-0104-trial
    D P Modest
    Department of Medicine III, University of Munich, Munich, Germany
    Int J Cancer 131:980-6. 2012
  7. doi request reprint Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Stu
    Sebastian Stintzing
    Department of Haematology and Oncology, Comprehensive Cancer Center, Klinikum Grosshadern, University of Munich, Munich, Germany
    Int J Cancer 132:236-45. 2013
  8. doi request reprint Analysis for prognostic factors of 60-day mortality: evaluation of an irinotecan-based phase III trial performed in the first-line treatment of metastatic colorectal cancer
    Clemens Giessen
    Department of Medical Oncology, Klinikum Grosshadern, University of Munich, Munich, Germany
    Clin Colorectal Cancer 10:317-24. 2011
  9. doi request reprint Progression-free survival as a surrogate endpoint for median overall survival in metastatic colorectal cancer: literature-based analysis from 50 randomized first-line trials
    Clemens Giessen
    Department of Medical Oncology, Klinikum Grosshadern and Comprehensive Cancer Center, Ludwig Maximilian University of Munich, Munich, Germany
    Clin Cancer Res 19:225-35. 2013
  10. pmc A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial
    Clemens Giessen
    Department of Medical Oncology, Klinikum Grosshadern, University of Munich, Germany
    BMC Cancer 11:367. 2011

Detail Information

Publications10

  1. doi request reprint [Chemotherapy of metastatic colorectal cancer]
    D P Modest
    Medizinische Klinik und Poliklinik III and Comprehensive Cancer Center, Klinikum der Universitat Munchen, Marchioninistr 15, 81377, Munchen, Deutschland
    Internist (Berl) 55:37-42. 2014
    ..The development of effective therapeutic strategies in patients with (K-)RAS mutant mCRC tumors must be promoted in the future and requires intensive research because the therapy options for this group of patients are very limited. ..
  2. pmc Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group
    Anke Reinacher-Schick
    Department of Internal Medicine, Knappschaftskrankenhaus, Ruhr University Bochum, Bochum, Germany
    BMC Cancer 12:349. 2012
    ..To evaluate the value of KRAS codon 13 mutations in patients with advanced colorectal cancer (advanced CRC) treated with oxaliplatin and fluoropyrimidines...
  3. doi request reprint KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer
    D P Modest
    Department of Medicine III, University Hospital Grosshadern, University of Munich, Munich, Germany
    J Cancer Res Clin Oncol 139:953-61. 2013
    ..To investigate the impact of different KRAS mutations on treatment with the tyrosine kinase inhibitor sunitinib in SW48 colorectal cancer cell line variants...
  4. ncbi request reprint Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials
    Dominik P Modest
    Department of Medicine III, University Hospital Grosshadern, University of Munich, Munich, Germany
    Oncology 83:241-7. 2012
    ..This study investigated the impact of specific mutations in codon 12 of the Kirsten-ras (KRAS) gene on treatment efficacy in patients with metastatic colorectal cancer (mCRC)...
  5. doi request reprint Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis
    Dominik Paul Modest
    Department of Medicine III, Klinikum Grosshadern, University of Munich, Munich, Germany
    Anticancer Drugs 23:666-73. 2012
    ..G13D mutant mCRC. The combination with capecitabine and irinotecan was associated with a more favourable outcome compared with infusional 5-FU and oxaliplatin...
  6. doi request reprint The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: an analysis of the AIO KRK-0104-trial
    D P Modest
    Department of Medicine III, University of Munich, Munich, Germany
    Int J Cancer 131:980-6. 2012
    ....
  7. doi request reprint Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Stu
    Sebastian Stintzing
    Department of Haematology and Oncology, Comprehensive Cancer Center, Klinikum Grosshadern, University of Munich, Munich, Germany
    Int J Cancer 132:236-45. 2013
    ..This effect of Cet-ST is independent of the KRAS mutation status, suggesting that Cet-ST rather relates to constitutional factors of the patient than alterations of the EGFR pathway in the tumour...
  8. doi request reprint Analysis for prognostic factors of 60-day mortality: evaluation of an irinotecan-based phase III trial performed in the first-line treatment of metastatic colorectal cancer
    Clemens Giessen
    Department of Medical Oncology, Klinikum Grosshadern, University of Munich, Munich, Germany
    Clin Colorectal Cancer 10:317-24. 2011
    ..7% and 5.0%. This analysis aimed to evaluate clinical and histopathologic factors associated with 60-day mortality in first-line therapy for metastatic colorectal cancer (mCRC)...
  9. doi request reprint Progression-free survival as a surrogate endpoint for median overall survival in metastatic colorectal cancer: literature-based analysis from 50 randomized first-line trials
    Clemens Giessen
    Department of Medical Oncology, Klinikum Grosshadern and Comprehensive Cancer Center, Ludwig Maximilian University of Munich, Munich, Germany
    Clin Cancer Res 19:225-35. 2013
    ....
  10. pmc A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial
    Clemens Giessen
    Department of Medical Oncology, Klinikum Grosshadern, University of Munich, Germany
    BMC Cancer 11:367. 2011
    ..The present study investigates the question whether this statement holds true also for bevacizumab-based first-line treatment including escalation- and de-escalation strategies...